Ethnic endotypes in paediatric atopic dermatitis depend on immunotype, lipid composition and microbiota of the skin
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Atopic dermatitis (AD) endotypes differ with ethnicity. We examined the skin microbiota, cytokine and lipid profiles in Greenlandic Inuit and Danish children with AD.
Methods
Twenty-five Inuit children with AD and 25 Inuit control children were clinically examined and compared to previously collected data from 25 Danish children with AD. Skin tape strips and skin swabs were collected from lesional and non-lesional skin. Levels of cutaneous immune biomarkers, free sphingoid bases and their (glycosyl)ceramides were analysed. Skin swabs were analysed with 16S rRNA and tuf gene for characterization of bacterial species communities.
Results
Bacterial β-diversity was significantly different between Inuit and Danish AD skin, in both lesional (p < 0.001) and non-lesional (p < 0.001) AD skin, and there was a higher relative abundance of Staphylococcus aureus in Danish compared to Inuit lesional (53% vs. 8%, p < 0.01) and non-lesional skin (55% vs. 5%, p < 0.001). Danish AD children had a higher α-diversity than Inuit children in non-lesional (p < 0.05) but not in lesional skin. Significantly higher levels of type 2 immunity cytokine interleukin (IL)-4 (p < 0.05) and IL-5 (p < 0.01) were identified in Inuit compared to Danish AD children. In contrast, IL-33 (p < 0.01) was higher in Danish lesional and non-lesional AD skin. Higher levels of long-chain glucosylceramide (GlcCER)[S](d26:1) were found in lesional (p < 0.001) and non-lesional (p < 0.001) Inuit skin compared with Danish AD skin. NMF levels were similar in Inuit and Danish AD skin.
Conclusion
Skin microbiota, cytokine and lipid composition differed significantly between Inuit and Danish children with AD and showed a stronger type 2 immune signature in Inuit children.
| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | Journal of the European Academy of Dermatology and Venereology |
| Vol/bind | 38 |
| Udgave nummer | 2 |
| Sider (fra-til) | 365-374 |
| Antal sider | 10 |
| ISSN | 0926-9959 |
| DOI | |
| Status | Udgivet - 2024 |
Bibliografisk note
Funding Information:
A. Ingham, S. Edslev, A. K. Ghauharali‐van der Vlugt, F. S. Stet, I. Jakasa and S. Kezic have no conflicts of interests. A. M. Andersson is funded by a grant from LEO Foundation (LF17037). J. Sølberg has received grants from the Novo Nordisk Foundation (NNF21OC0066694) and the Capital Region of Denmark (A7251). A. Koch has received travel grants from Tillots Pharma. C. M. Brüggen has received grants and research funding from the Swiss National Science foundation (SNF), Christine Kühne Center for Allergy Research and Education (CK‐CARE), Freenovation Foundation, LEO Foundation, Olga Mayenfisch Foundation, the University of Zurich, LEO Pharma, the Eczema Foundation of Pierre Fabre, SwissLife Foundation, Vontobel Foundation, EMDO Foundation. Speaking and/or consultation fees from Eli Lilly, LEO Pharma, AbbVie and AstraZeneca. Speaking honoraria/presentations, educational events: CK‐CARE, FOMF and ADR‐AC. L. Skov has been a paid speaker for AbbVie, Eli Lilly, Novartis and LEO Pharma, and has been a consultant or has served on Advisory Boards with AbbVie, Janssen Cilag, Novartis, Eli Lilly, LEO Pharma, UCB, BMS, Boehringer Ingelheim, Almirall and Sanofi. She has served as an investigator for AbbVie, Sanofi, Janssen Cilag, Boehringer Ingelheim, AstraZenica, Eli Lilly, Novartis, Regeneron and LEO Pharma, and has received research and grants from UCB, BMS, Almirall Janssen Cilag and LEO Pharma. J. Thyssen is a full‐time employee at LEO Pharma, an advisor for AbbVie, Almirall, Arena Pharmaceuticals, Coloplast, OM Pharma, Aslan Pharmaceuticals, Union Therapeutics, Eli Lilly & Co, LEO Pharma, RAPT Therapeutics, Pfizer, Regeneron, and Sanofi‐Genzyme, a speaker for AbbVie, Almirall, Eli Lilly & Co, LEO Pharma, Pfizer, Regeneron and Sanofi‐Genzyme, and received research grants from Pfizer, Regeneron and Sanofi‐Genzyme.
Funding Information:
This study was supported by a grant from LEO Foundation.
Publisher Copyright:
© 2023 European Academy of Dermatology and Venereology.
ID: 381143793